Home » Stocks » OCX

OncoCyte Corporation (OCX)

Stock Price: $4.92 USD -0.42 (-7.87%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 431.04M
Revenue (ttm) 714,000
Net Income (ttm) -31.58M
Shares Out 67.25M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $4.92
Previous Close $5.34
Change ($) -0.42
Change (%) -7.87%
Day's Open 5.24
Day's Range 4.92 - 5.59
Day's Volume 950,591
52-Week Range 1.15 - 6.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

IRVINE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision p...

GlobeNewsWire - 2 weeks ago

IRVINE, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision p...

The Motley Fool - 3 weeks ago

The announcement of a new share issue usually drives a stock's price down, after all.

GlobeNewsWire - 3 weeks ago

IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision p...

Benzinga - 3 weeks ago

Oncocyte Corporation (NYSE: OCX) has agreed to acquire Chronix Biomedical, a privately held molecular diagnostics company, developing blood tests for cancer treatment and organ transplants. Th...

GlobeNewsWire - 3 weeks ago

Transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing

Benzinga - 1 month ago

OncoCyte Corp (NYSE: OCX) shares are advancing to their highest level since the middle of 2019 on above-average volume. Oncocyte said it has entered into definitive agreements with its two lar...

GlobeNewsWire - 1 month ago

Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings

GlobeNewsWire - 1 month ago

IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision p...

InvestorPlace - 1 month ago

Which of our experts will win the best stocks contest? They're all betting on themes likely to dominate in 2021 and beyond.

Other stocks mentioned: BBBY, EPD, FVRR, IZEA, LMT, NIO, OR, WBA, DIS
InvestorPlace - 1 month ago

One of the top stocks to buy for 2021 is OncoCyte, a molecular diagnostics company that offers genetic testing to physicians and patients. The post Best Stocks for 2021: OncoCyte (OCX) appeare...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.

InvestorPlace - 2 months ago

Shares of OCX stock are blasting off on Tuesday morning after a major company agreement with an important China-based biotech firm. The post OCX Stock: Why Shares of Biotech OncoCyte Are Skyro...

Market Watch - 2 months ago

Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing...

Other stocks mentioned: BNR
GlobeNewsWire - 2 months ago

IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision p...

GlobeNewsWire - 2 months ago

Physician researchers from Yale Cancer Center and University of California San Francisco (UCSF) to present on test performance in immunotherapy and chemotherapy selection Physician researchers...

Benzinga - 2 months ago

Jaguar Health (NASDAQ: JAGX) shares are trading higher on Monday after the company announced its plans to develop and commercialize its Crofelemer. Jaguar Health is a commercial-stage pharmace...

Other stocks mentioned: JAGX
GlobeNewsWire - 3 months ago

IRVINE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision p...

GlobeNewsWire - 3 months ago

Data demonstrate that DetermaIO™  can be run successfully using limited tissue from small biopsy specimens , overcoming the significant challenge s associated with tissue availability for mole...

Seeking Alpha - 3 months ago

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

Data show DetermaIO™ may help to select effective therapeutic options for immune checkpoint inhibitor (ICI) resistant patients with non-small cell lung cancer (NSCLC) and triple-negative breas...

GlobeNewsWire - 3 months ago

Oncocyte named in Top 5 as one of Orange County's Best Places to Work in 2020 in its first year Oncocyte named in Top 5 as one of Orange County's Best Places to Work in 2020 in its first year

GlobeNewsWire - 4 months ago

Testing volume for DetermaRx more than doubled in Q3 202 0

GlobeNewsWire - 4 months ago

Chronix’s blood - based test monitors the effectiveness of immunotherapy drugs in clinical trials , and potentially in patients receiving immunotherapy treatment

GlobeNewsWire - 5 months ago

IRVINE, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decisio...

GlobeNewsWire - 5 months ago

Pricing in line with comparable high-value molecular tests for oncology indications

GlobeNewsWire - 5 months ago

Collaboration establishes an integrated platform for precision medicine clinical trials, combining Oncocyte’s proprietary molecular tests and fully certified pharma services lab with GRN’s nat...

GlobeNewsWire - 6 months ago

IRVINE, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision...

GlobeNewsWire - 6 months ago

IRVINE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision...

GlobeNewsWire - 6 months ago

Event to feature Dr. Naoto Ueno, study investigator and medical oncologist at the University of Texas MD Anderson Cancer Center

Seeking Alpha - 6 months ago

Oncocyte Corporation's (OCX) CEO Ronnie Andrews on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

OncoCyte (OCX) delivered earnings and revenue surprises of -27.27% and 257.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

 Secured National Medicare Reimbursement for DetermaRx™ Starting August 2020 with Final Medicare LCD from Palmetto GBA and Noridian Healthcare Solutions

GlobeNewsWire - 7 months ago

Event to feature renowned lung cancer experts Dr. David Gandara and Dr. Johannes Kratz

GlobeNewsWire - 7 months ago

IRVINE, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision...

GlobeNewsWire - 7 months ago

Noridian's decision aligns with Palmetto GBA's final LCD for the test announced in April

GlobeNewsWire - 7 months ago

Oncocyte continues global expansion of DetermaRx with its second international agreement this year Oncocyte continues global expansion of DetermaRx with its second international agreement this...

GlobeNewsWire - 7 months ago

Testing volume for DetermaRx™ doubled from Q1 2020 to Q2 2020 despite challenging COVID-19 macroenvironment Testing volume for DetermaRx™ doubled from Q1 2020 to Q2 2020 despite challenging CO...

Seeking Alpha - 7 months ago

Oncocyte: Despite The Bad Result Of DetermaDX The Comany Still Has Bullish Potential

Seeking Alpha - 7 months ago

On June 29 OncoCyte reported the results of the clinical validation of the DetermaDx test with very bad news: The results obtained failed to reach the target set.

GlobeNewsWire - 7 months ago

 Prospective, blinded clinical validation study did not achieve pre-defined endpoint of improvement over routinely used clinical factors for managing patients with radiologically identified lu...

GlobeNewsWire - 8 months ago

Oncocyte has received its first diagnostic revenues from commercial payers

Seeking Alpha - 8 months ago

OncoCyte: Already A Commercial Stage Company With Enormous Revenue Potential

Seeking Alpha - 9 months ago

Oncocyte Corporation (OCX) CEO Ronald Andrews on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Announced Final Medicare LCD from Palmetto for DetermaRx™, Potentially Establishing Medicare Coverage for up to 70% of Eligible Early-Stage NSCLC Patients

GlobeNewsWire - 9 months ago

Abstracts selected for oral presentation at the American Thoracic Society 2020 International Conference and published in American Journal of Respiratory and Clinical Care Medicine

GlobeNewsWire - 9 months ago

May lead to Medicare coverage for up to 70% of eligible early-stage lung cancer patients May lead to Medicare coverage for up to 70% of eligible early-stage lung cancer patients

GlobeNewsWire - 10 months ago

Further strengthens balance sheet to support ongoing commercial and development activities Further strengthens balance sheet to support ongoing commercial and development activities

Zacks Investment Research - 10 months ago

Medical Services Outlook Bright Amid Coronavirus Crisis

Other stocks mentioned: CODX, ESTA, NVCR
Seeking Alpha - 11 months ago

OncoCyte Corporation (OCX) CEO Ronald Andrews on Q4 2019 Results - Earnings Call Transcript

About OCX

OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals... [Read more...]

Industry
Biotechnology
Founded
2009
CEO
Ronald A. Andrews Jr.
Employees
33
Stock Exchange
NYSEAMERICAN
Ticker Symbol
OCX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for OncoCyte stock is "Buy." The 12-month stock price forecast is 6.14, which is an increase of 24.80% from the latest price.

Price Target
$6.14
(24.80% upside)
Analyst Consensus: Buy